Roxadustat Global Market Report 2025

The Roxadustat market size has grown strongly in recent years. It will grow from $6.44 billion in 2024 to $6.92 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth during the historic period can be attributed to regulatory approvals in major markets, strong clinical trial results, the increasing prevalence of chronic kidney disease, rising awareness of anemia management, and government support for anemia treatments.

The Roxadustat market size is expected to see strong growth in the next few years. It will grow to $9.16 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to ongoing research for new indications, increasing healthcare expenditure, rising demand for non-injectable anemia treatments, expanding reimbursement policies, and a growing geriatric population. Major trends include a shift toward oral anemia treatments, increasing competition from alternative therapies, the expansion of licensing agreements, growing investment in hypoxia-inducible factor research, and a stronger focus on patient-centric treatment approaches.

The rising prevalence of chronic kidney disease (CKD) is expected to drive the growth of the Roxadustat market. CKD is a progressive condition where kidney function deteriorates over time, often leading to kidney failure if not properly managed. The increasing incidence of CKD is primarily due to aging populations, higher rates of diabetes and hypertension, and unhealthy lifestyle choices. Roxadustat is a key treatment for managing CKD-related anemia by stimulating erythropoietin production, which boosts red blood cell levels and enhances overall kidney function and patient quality of life. For instance, in December 2024, the Australian Institute of Health and Welfare (AIHW), an Australia-based government agency, reported an annual rise in CKD mortality rates, with increases of 4.2% in 2021 and 6.2% in 2022. As a result, the growing number of CKD cases is fueling the demand for Roxadustat.

The expansion of reimbursement programs, such as Ireland’s High-Tech Drugs Scheme, is accelerating Roxadustat’s market growth by making it more accessible to patients. The High-Tech Drugs Scheme, a government-managed program in Ireland, covers high-cost, specialized medications, reducing financial barriers for patients and supporting broader adoption. For example, in September 2022, Astellas Pharma Company Ltd., a US-based pharmaceutical company, announced that EVRENZO (Roxadustat) received reimbursement under Ireland’s High-Tech Drugs Scheme. Roxadustat, the first orally administered hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor approved in Ireland, demonstrated effectiveness in achieving and maintaining target hemoglobin levels (10-12g/dL) in CKD patients, regardless of their dialysis status or previous erythropoiesis-stimulating agent (ESA) treatment. Such reimbursement initiatives are expected to enhance patient access and drive market expansion.

In February 2024, FibroGen Inc., a US-based biopharmaceutical company, partnered with Astellas Pharma Inc. and AstraZeneca PLC to further develop and distribute Roxadustat for anemia associated with CKD and other conditions, such as myelodysplastic syndromes (MDS). Astellas Pharma, a Japan-based pharmaceutical company, and AstraZeneca, a UK-based pharmaceutical giant, bring extensive expertise in global commercialization, further boosting Roxadustat’s market potential. These partnerships highlight the growing investment and focus on expanding treatment options for CKD-related anemia, solidifying Roxadustat’s position in the market.

Major players in the Roxadustat market are AstraZeneca PLC, Viatris Inc., Astellas Pharma Inc., Dr. Reddy's Laboratories Ltd., Hetero Drugs Limited, Akebia Therapeutics Inc., Metrochem API Private Limited, FibroGen Inc., AMI Lifesciences, Lee Pharma Ltd., Faran Shimi Pharmaceutical Company, Maithri Drugs Pvt. Ltd., Clearsynth Labs Ltd., Bal Pharma, HEMA Pharmaceuticals Pvt. Ltd., Zhejiang Hengkang Pharmaceutical Co. Ltd., Kimia Biosciences Pvt. Ltd., Lewens Labs Pvt. Ltd., Hangzhou Longshine Bio-Tech Co. Ltd., GLR Innovations, Suzhou Biosyntech Co. Ltd., Shanvr Life Sciences Pvt. Ltd.

North America was the largest region in the Roxadustat market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in Roxadustat report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the Roxadustat market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Roxadustat is an orally administered hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) that stabilizes hypoxia-inducible factors, promoting increased erythropoietin production, enhanced iron absorption, and improved hemoglobin synthesis without requiring exogenous erythropoiesis-stimulating agents. It is primarily used to manage anemia by addressing low hemoglobin levels in patients with chronic kidney disease and potentially other conditions involving impaired red blood cell production.

The main types of Roxadustat include 20 mg and 50 mg formulations. The 20 mg variant is an oral HIF-PHI used for treating anemia associated with chronic kidney disease by stimulating endogenous erythropoietin production. Roxadustat is available in oral tablet form and is distributed through hospitals, specialty pharmacies, and dialysis centers. It is primarily used for chronic kidney disease-associated anemia and other related conditions.

The Roxadustat market research report is one of a series of new reports that provides Roxadustat market statistics, including Roxadustat industry global market size, regional shares, competitors with a Roxadustat market share, detailed Roxadustat market segments, market trends and opportunities, and any further data you may need to thrive in the Roxadustat industry. This Roxadustat market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The Roxadustat market consists of sales of products such as 70 mg, 100 mg, and 150 mg film-coated tablets. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.